


=> d l1
 L1 HAS NO ANSWERS
 L1



REP G1=(0-3) C
 VAR G2=O/S/N/C
 VAR G3=11/12/13
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

=> s l1 ful
 FULL SEARCH INITIATED 13:16:42 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 1726 TO ITERATE


100.0% PROCESSED 1726 ITERATIONS
 SEARCH TIME: 00.00.01

135 ANSWERS

L3 135 SEA SSS FUL L1

=> d scan

L3 135 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-3-chloro-N-
 hydroxy- (9CI)
 MF C18 H16 Cl N O5 S



=> s 13

L4 3 L3

=> d bib abs 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS

AN 2002:66852 CAPLUS

DN 136:118280

TI Preparation of N-hydroxy[(alkynyloxy)phenylsulfanyl]alkanoamides and analogs as TACE and MMP inhibitors

IN Levin, Jeremy I.; Venkatesan, Aranapakam M.; Cole, Derek C.; Chen, James M.; Davis, Jamie M.; Grosu, George T.

PA American Cyanamid Company, USA

SO U.S., 43 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6340691	B1	20020122	US 2000-492977	20000127
	US 2002147342	A1	20021010	US 2001-55502	20011113
PRAI	US 1999-160085P	P	19990127		
	US 2000-492977	A3	20000127		

OS MARPAT 136:118280

AB R1C.tplbond.CCR2R3Z1Z2Z3CR8R9ZCON(OH)R12 [I; R1 = H, alkyl, (hetero)aryl, etc.; R2,R3 = H, cyano, alkyl, CCH (sic); R8,R9 = H, aryl(alkyl), heteroaryl, etc.; R12 = H, heterocyclyl, (hetero)aryl, etc.; Z = bond, (un)substituted CH2, -CH2CH2; Z1 = O, SO0-2, (un)substituted NH, C (sic); Z2 = (hetero)arylene; Z3 = O, SO0-2, (un)substituted NH, CH (sic)] were prepd. Thus, MeCHBrCO2Et was thioetherified by 4-(HO)C6H4SH and the product etherified by MeC.tplbond.CCH2Br to give, in 2 addnl. steps, 4-(MeC.tplbond.CCH2O)C6H4SCHMeCONHOH. Data for biol. activity of I were given.

RE.CNT 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS

AN 2001:762982 CAPLUS

DN 135:318704

TI Preparation of benzimidazole-, benzoxazole- and benzothiazolesulfonamide amino acid derivatives as selective matrix metalloproteinase inhibitors

IN Park, Young-Jun; Bae, Hae-Young; Yoo, Ji-Uk; Chae, Myeong-Yun; Paek, Sang-Hyun; Min, Hye-Kyung; Park, Hyun-Gyu; Ryu, Choon-Ho; Kim, Kyung-Chul; Lee, Jeoung-Wook

PA Samsung Electronics Co., Ltd., S. Korea

SO PCT Int. Appl., 115 pp.

CODEN: PIXXD2





DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001077092	A1	20011018	WO 2001-KR585	20010407
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1208092 A1 20020529 EP 2001-922101 20010407
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2002169314 A1 20021114 US 2001-18507 20011206
 PRAI KR 2000-18327 A 20000407
 KR 2000-18328 A 20000407
 KR 2000-18431 A 20000408
 WO 2001-KR585 W 20010407
 OS MARPAT 135:318704
 GI



AB The present invention provides novel sulfonamide derivs. (I (e.g. (2R)-3-methyl-2-[(2-phenylthiobenzothiazole-6-sulfonyl)amino]butanoic acid Me ester), II (n = 0-4) and III (n = 0-4)), useful as an inhibitors of matrix metalloproteinase (MMP), its isomers, pharmaceutically acceptable salts thereof and a process for prep. the same. Since the sulfonamide derivs. of the present invention selectively inhibit MMP activity in vitro, the MMP inhibitors comprising the sulfonamide derivs. as an effective ingredient can be practically applied for the prevention and treatment of all sorts of diseases caused by overexpression and overactivation of MMP. In I: R1 denotes H, C1-12 alkyl, carbocyclic aryl-lower alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-lower alkyl, (oxo, amino or thio) C3-7 cycloalkyl, (oxo, amino or thio) C3-7 cycloalkyl-lower alkyl, C2-12 lower alkenyl, C2-12 lower alkynyl, carbocyclic aryl, heterocyclic aryl, heterocyclic aryl-lower alkyl, biaryl, halo lower alkyl, biaryl-lower alkylarylalkyl, hydroxy-lower alkyl, alkoxyalkyl, acyloxy-lower alkyl, alkyl or aryl (thio, sulfinyl or sulfonyl) lower alkyl, (amino, mono or dialkylamino) lower alkyl, acylamino lower alkyl, (N-lower alkylpiperazino, or N-carbocyclic or heterocyclic aryl-lower alkylpiperazino)-lower alkyl or (morpholino, thiomorpholino, piperidino, pyrrolidino or piperidyl)-lower alkyl. R2 denotes H, lower alkyl, carbocyclic aryl-lower alkyl, C1-4 carbocyclic aryl-lower alkyl, C1-4 heterocyclic aryl-lower alkyl, C1-5 alkoxyphenyl-lower alkyl, C1-5 alkenoxyphenyl-lower alkyl, C1-5 alkynoxyphenyl-lower alkyl, heterocyclic aryl-lower alkyl, hydroxy-lower alkyl, alkoxyalkyl, acyloxy-lower alkyl, thio-lower alkyl, alkyl or aryl-(thio, sulfinyl or sulfonyl) lower alkyl,

(amino, mono or dialkylamino) lower alkyl, carboxy-lower alkyl, (amino, mono or dialkylamino) lower alkyl or acylamino lower alkyl. R3 denotes H or C1-6-lower alkyl. R4 denotes H, C1-12 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-lower alkyl, (oxo, amino or thio) C3-7 cycloalkyl, (oxo, amino or thio) C3-7 cycloalkyl-lower alkyl, carbocyclic aryl, carbocyclic aryl-lower alkyl, heterocyclic aryl, heterocyclic aryl-lower alkyl, biaryl, biaryl-lower alkyl, halo lower alkyl, hydroxy-lower alkyl, alkoxyalkyl, acyloxy-lower alkyl, alkyl or aryl-(thio, sulfinyl or sulfonyl) lower alkyl, (amino, mono or dialkylamino) lower alkyl, acylamino lower alkyl, carboxy lower alkyl, (N-lower alkylpiperazino, or N-carbocyclic or heterocyclic aryl piperazino)-lower alkyl or (morpholino, thiomorpholino, piperidino, pyrrolidino or piperidyl)-lower alkyl. R5 denotes hydroxy, alkoxy, halogen, thiol, thioalkoxy or hydroxylamine. X1 and X2 denote N-R7 (R7 is H, C1-6-lower alkyl, aryl, heteroaryl or arylalkyl), S or O. I can be prepd. by (i) reacting a sulfonyl halide with H2NCR2R3CO2R6 (R6 = protecting group) in an org. solvent in the presence of a base to give a sulfonamide; (ii) replacing the H on N using R4-L (L = reactive leaving group) in an org. solvent in the presence of a base; and (iii) hydrolyzing the intermediate to give I (R5 = OH), or further condensing I (R5 = OH) to prep. I (R5 = NHOH). Alternatively, I can be prepd. by (i) chlorosulfonylating IV; (ii) reacting this intermediate with an amino acid deriv. in an org. solvent in the presence of base to give a sulfonamide; (iii) heating this intermediate and R1-X2H together at 70 to 80.degree. in an org. solvent in the presence of base to cause substitution for Cl; (iv) reacting this intermediate with R4-L (L = reactive leaving group) in an org. solvent in the presence of base to cause substitution for H on N; and, (v) hydrolyzing this intermediate into I (R5 = OH), or further condensing I (R5 = OH) to prep. I (R5 = NHOH). .apprx.70 Example preps. of intermediates and products are given. Inhibition rates for some of the claimed compds. are reported for gelatinase A (MMP-2), gelatinase B (MMP-9) and collagenase (MMP-1).

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS

AN 2000:535106 CAPLUS

DN 133:150348

TI Preparation of alkynyl containing hydroxamic acid compounds as TACE inhibitors

IN Levin, Jeremy Ian; Venkatesan, Aranapakam Mudumbai; Cole, Derek Cecil; Chen, James Ming; Davis, Jamie Marie; Grosu, George Theodore

PA American Cyanamid Company, USA

SO PCT Int. Appl., 125 pp.

CODEN: PIXXD2



DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000044713	A1	20000803	WO 2000-US2078	20000127
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2356346	AA	20000803	CA 2000-2356346	20000127
	EP 1147080	A1	20011024	EP 2000-911652	20000127
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

BR 2000007783	A	20020205	BR 2000-7783	20000127
NO 2001003677	A	20010920	NO 2001-3677	20010726
PRAI US 1999-239088	A	19990127		
WO 2000-US2078	W	20000127		
OS MARPAT 133:150348				
GI				



AB The title compds. [I; R1 = H, aryl, heteroaryl, etc.; R2, R3 = H, alkyl, CN, CCH; R8-R11 = H, aryl, aralkyl, etc.; R12 = H, aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S, O, etc.; A = O, S, SO, etc.; X = O, S, SO, etc.; Y = aryl, heteroaryl, with the proviso that A and X are not bonded to adjacent atoms of Y; n = 0-2] and their pharmaceutically acceptable salts, useful in treating disease conditions mediated by TNF- α , such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss, were prepd. E.g., a multi-step synthesis of II.HCl which showed IC50 of 191 nM against TACE, and IC50 of 2 nM, 180 nM, and 200 nM against MMP-1, MMP-9, and MMP-13, resp., was given.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d hitstr 1

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS

IT 287391-43-9P 287391-44-0P 287391-45-1P
287391-46-2P 287391-47-3P 287391-48-4P
287391-49-5P 287391-50-8P 287391-51-9P
287391-52-0P 287391-53-1P 287391-54-2P
287391-55-3P 287391-56-4P 287391-57-5P
287391-58-6P 287391-59-7P 287391-60-0P
287391-61-1P 287391-62-2P 287391-63-3P
287391-64-4P 287391-65-5P 287391-66-6P
287391-67-7P 287391-68-8P 287391-69-9P


287391-70-2P 287391-71-3P 287391-72-4P
 287391-73-5P 287391-74-6P 287391-75-7P
 287391-76-8P 287391-77-9P 287391-78-0P
 287391-79-1P 287391-80-4P 287391-81-5P
 287391-82-6P 287391-83-7P 287391-84-8P
 287391-85-9P 287391-86-0P 287391-87-1P
 287391-88-2P 287391-89-3P 287391-90-6P
 287391-91-7P 287391-92-8P 287391-93-9P
 287391-94-0P 287391-95-1P 287391-96-2P
 287391-97-3P 287391-98-4P 287391-99-5P
 287392-00-1P 287392-01-2P 287392-02-3P
 287392-03-4P 287392-04-5P 287392-05-6P
 287392-06-7P 287392-07-8P 287392-08-9P
 287392-09-0P 287392-10-3P 287392-11-4P
 287392-12-5P 287392-13-6P 287392-14-7P
 287392-15-8P 287392-16-9P 287392-17-0P
 287392-19-2P 287392-21-6P 287392-22-7P
 287392-24-9P 287392-25-0P 287392-26-1P
 287392-27-2P 287392-28-3P 287392-29-4P
 287392-30-7P 287392-31-8P 287392-32-9P
 287392-33-0P 287392-34-1P 287392-36-3P
 287392-37-4P 287392-38-5P 287392-39-6P
 287392-40-9P 287392-41-0P 287392-42-1P
 287392-43-2P 287392-44-3P 287392-45-4P
 287392-46-5P 287392-47-6P 287392-48-7P
 287392-49-8P 287392-50-1P 287392-51-2P
 287392-52-3P 287392-53-4P 287392-54-5P
 287392-55-6P 287392-56-7P 287392-57-8P
 287392-58-9P 287392-59-0P 287392-60-3P
 287392-61-4P 287392-62-5P 287392-63-6P
 287392-64-7P 287392-65-8P 287392-66-9P
 287392-67-0P 287392-68-1P 287393-60-6P
 287393-61-7P 390400-53-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of N-hydroxy[(alkynyloxy)phenylsulfanyl]alkanoamides and
 analogs as TACE and MMP inhibitors)

RN 287391-43-9 CAPLUS


CN Benzenepropanamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-
 .alpha.-methyl-4-[2-(1-piperidinyl)ethoxy]-, monohydrochloride (9CI) (CA
 INDEX NAME)




HCl

RN 287391-44-0 CAPLUS

CN [1,1'-Biphenyl]-4-propanamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-
 N-hydroxy-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 287391-45-1 CAPLUS
 CN 3-Pyridinepropanamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-.alpha.-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 287391-46-2 CAPLUS
 CN Propanamide, 2-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 287391-47-3 CAPLUS
 CN Octanamide, 2-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287391-48-4 CAPLUS
 CN Octanamide, 2-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 287391-49-5 CAPLUS

CN Octanamide, 2-[(R)-[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287391-50-8 CAPLUS


CN Octanamide, 2-[(S)-[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287391-51-9 CAPLUS

CN Propanamide, 3-[4-(2-butynyloxy)phenoxy]-N-hydroxy- (9CI) (CA INDEX NAME)



=> d hitstr 3

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS


IT 287391-48-4P 287392-15-8P 287392-16-9P
287392-19-2P 287392-25-0P 287392-26-1P
287392-30-7P 287392-31-8P 287392-32-9P
287392-34-1P 287392-35-2P 287392-37-4P
287392-42-1P 287392-44-3P 287392-46-5P
287392-50-1P 287392-54-5P 287392-57-8P
287392-60-3P 287392-66-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of alkynyl contg. hydroxamic acid compds. as TACE inhibitors)


RN 287391-48-4 CAPLUS

CN Octanamide, 2-[4-(2-butyloxy)phenylthio]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-15-8 CAPLUS

CN Cyclohexaneacetamide, .alpha.-[4-(2-butyloxy)phenylthio]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-16-9 CAPLUS

CN Cyclohexaneacetamide, .alpha.-[4-(2-butyloxy)phenylsulfinyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-19-2 CAPLUS

CN Benzeneacetamide, .alpha.-[4-(2-butyloxy)phenylthio]-N-hydroxy-4-methoxy- (9CI) (CA INDEX NAME)




RN 287392-25-0 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]thio]-4-chloro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-26-1 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-4-chloro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 287392-30-7 CAPLUS


CN Benzeneacetamide, 4-bromo-.alpha.-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 287392-31-8 CAPLUS


CN Benzeneacetamide, 4-bromo-.alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287392-32-9 CAPLUS
 CN Benzeneacetamide, 4-bromo-.alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 287392-34-1 CAPLUS
 CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy-4-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 287392-35-2 CAPLUS
 CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-4-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 287392-37-4 CAPLUS
 CN 1-Naphthaleneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-42-1 CAPLUS

CN Benzeneacetamide, .alpha.-[4-(2-butynyloxy)phenyl]thio]-N-hydroxy-2-methoxy- (9CI) (CA INDEX NAME)




RN 287392-44-3 CAPLUS

CN Benzeneacetamide, .alpha.-[4-(2-butynyloxy)phenyl]thio]-4-ethoxy-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-46-5 CAPLUS

CN Benzeneacetamide, 3-bromo-.alpha.-[4-(2-butynyloxy)phenyl]thio]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-50-1 CAPLUS

CN Butanamide, 2-[4-(2-butynyloxy)phenyl]thio]-N-hydroxy-3-methyl- (9CI) (CA INDEX NAME)




RN 287392-54-5 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy- (9CI)
(CA INDEX NAME)




RN 287392-57-8 CAPLUS

CN 2-Naphthaleneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy- (9CI)
(CA INDEX NAME)




RN 287392-60-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[1-[[4-(2-butynyloxy)phenyl]sulfonyl]-2-(hydroxyamino)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RN 287392-66-9 CAPLUS

CN 2H-Thiopyran-4-acetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI)
(CA INDEX NAME)




IT 287391-43-9P 287391-44-0P 287391-45-1P
 287391-46-2P 287391-47-3P 287391-49-5P
 287391-50-8P 287391-51-9P 287391-52-0P
 287391-53-1P 287391-54-2P 287391-55-3P
 287391-56-4P 287391-57-5P 287391-58-6P
 287391-59-7P 287391-60-0P 287391-61-1P
 287391-62-2P 287391-63-3P 287391-64-4P
 287391-65-5P 287391-66-6P 287391-67-7P
 287391-68-8P 287391-69-9P 287391-70-2P
 287391-71-3P 287391-72-4P 287391-73-5P
 287391-74-6P 287391-75-7P 287391-76-8P
 287391-77-9P 287391-78-0P 287391-79-1P
 287391-80-4P 287391-81-5P 287391-82-6P
 287391-83-7P 287391-84-8P 287391-85-9P
 287391-86-0P 287391-87-1P 287391-88-2P
 287391-89-3P 287391-90-6P 287391-91-7P
 287391-92-8P 287391-93-9P 287391-94-0P
 287391-95-1P 287391-96-2P 287391-97-3P
 287391-98-4P 287391-99-5P 287392-00-1P
 287392-01-2P 287392-02-3P 287392-03-4P
 287392-04-5P 287392-05-6P 287392-06-7P
 287392-07-8P 287392-08-9P 287392-09-0P
 287392-10-3P 287392-11-4P 287392-12-5P
 287392-13-6P 287392-14-7P 287392-17-0P
 287392-21-6P 287392-22-7P 287392-24-9P
 287392-27-2P 287392-28-3P 287392-29-4P
 287392-33-0P 287392-36-3P 287392-38-5P
 287392-39-6P 287392-40-9P 287392-41-0P
 287392-43-2P 287392-45-4P 287392-47-6P
 287392-48-7P 287392-49-8P 287392-51-2P
 287392-52-3P 287392-53-4P 287392-55-6P
 287392-56-7P 287392-58-9P 287392-59-0P
 287392-61-4P 287392-62-5P 287392-63-6P
 287392-64-7P 287392-65-8P 287392-67-0P
 287392-68-1P 287393-60-6P 287393-61-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of alkynyl contg. hydroxamic acid compds. as TACE inhibitors)


RN 287391-43-9 CAPLUS

CN Benzenepropanamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-.alpha.-methyl-4-[2-(1-piperidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 287391-44-0 CAPLUS
 CN [1,1'-Biphenyl]-4-propanamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 287391-45-1 CAPLUS
 CN 3-Pyridinepropanamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-.alpha.-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 287391-46-2 CAPLUS
 CN Propanamide, 2-[[4-(2-butynyloxy)phenyl]thio]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 287391-47-3 CAPLUS
 CN Octanamide, 2-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)


INDEX NAME)



RN 287391-49-5 CAPLUS

CN Octanamide, 2-[(R)-[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287391-50-8 CAPLUS


CN Octanamide, 2-[(S)-[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287391-51-9 CAPLUS

CN Propanamide, 3-[4-(2-butynyloxy)phenoxy]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287391-52-0 CAPLUS

CN Butanamide, 4-[4-(2-butynyloxy)phenoxy]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287391-53-1 CAPLUS

CN Acetamide, 2-[4-(2-butynyloxy)phenoxy]-N-hydroxy (9CI) (CA INDEX NAME)




RN 287391-54-2 CAPLUS

CN Benzenebutanamide, 4-(2-butynyloxy)-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287391-55-3 CAPLUS

CN 2H-Isoindole-2-acetamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)



RN 287391-56-4 CAPLUS


CN 2-Quinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)



RN 287391-57-5 CAPLUS


CN Benzamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-

oxohexyl]-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 287391-58-6 CAPLUS

CN Benzeneacetamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]-3,4-dichloro- (9CI) (CA INDEX NAME)




RN 287391-59-7 CAPLUS

CN 3-Quinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-60-0 CAPLUS

CN 2-Thiophenebutanamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-61-1 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-62-2 CAPLUS

CN Benzeneacetamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]-.alpha.-phenyl- (9CI) (CA INDEX NAME)




RN 287391-63-3 CAPLUS

CN 1-Isoquinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-64-4 CAPLUS

CN Benzo[b]thiophene-3-acetamide, N-[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-65-5 CAPLUS

CN 2-Quinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-66-6 CAPLUS

CN 2H-Isoindole-2-acetamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)




RN 287391-67-7 CAPLUS

CN Benzamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 287391-68-8 CAPLUS

CN Benzeneacetamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]-3,4-dichloro- (9CI) (CA INDEX NAME)




RN 287391-69-9 CAPLUS

CN 3-Quinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]-2,4-dichlorophenyl (CA INDEX NAME)




RN 287391-70-2 CAPLUS

CN 2-Thiophenebutanamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]-9-quinolinecarboxamide (CA INDEX NAME)




RN 287391-71-3 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]-thiophenyl (CA INDEX NAME)




RN 287391-72-4 CAPLUS

CN Benzeneacetamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]-phenyl (CA INDEX NAME)




RN 287391-73-5 CAPLUS

CN 1-Isoquinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-74-6 CAPLUS

CN Benzo[b]thiophene-3-acetamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-75-7 CAPLUS

CN 1H-Indole-3-acetamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-76-8 CAPLUS

CN Benzamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 287391-77-9 CAPLUS

CN 2-Quinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-78-0 CAPLUS

CN 2H-Isoindole-2-acetamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)




RN 287391-79-1 CAPLUS

CN Benzeneacetamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]-3,4-dichloro- (9CI) (CA INDEX NAME)




RN 287391-80-4 CAPLUS

CN 3-Quinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-81-5 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)




RN 287391-82-6 CAPLUS

CN Benzeneacetamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]-.alpha.-phenyl- (9CI) (CA INDEX NAME)




RN 287391-83-7 CAPLUS

CN 1-Isoquinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)



RN 287391-84-8 CAPLUS


CN Benzo[b]thiophene-3-acetamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]-(9CI) (CA INDEX NAME)




RN 287391-85-9 CAPLUS

CN Benzeneacetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-3,4-dichloro-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 287391-86-0 CAPLUS

CN 2-Quinolinecarboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

$\equiv \text{C}-\text{Me}$

RN 287391-87-1 CAPLUS
 CN 2H-Isoindole-2-acetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-1,3-dihydro-1,3-dioxo- (9CI)
 (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


$-\text{C}\equiv\text{C}-\text{Me}$

RN 287391-88-2 CAPLUS
 CN Benzamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 287391-89-3 CAPLUS
 CN 3-Quinolinecarboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


$\equiv \text{C}-\text{Me}$

RN 287391-90-6 CAPLUS
 CN 9H-Xanthene-9-carboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 287391-91-7 CAPLUS
 CN Benzeneacetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-.alpha.-phenyl- (9CI) (CA INDEX NAME)




RN 287391-92-8 CAPLUS
 CN 1-Isoquinolinecarboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 287391-93-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 287391-94-0 CAPLUS

CN Benzo[b]thiophene-3-acetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]thio]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 287391-95-1 CAPLUS

CN 3-Quinolinecarboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 287391-96-2 CAPLUS

CN 2-Quinolinecarboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-A




PAGE 1-B

$\equiv \text{C}-\text{Me}$

RN 287391-97-3 CAPLUS
 CN 2H-Isoindole-2-acetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-1,3-dihydro-1,3-dioxo- (9CI)
 (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


$-\text{C}\equiv\text{C}-\text{Me}$

RN 287391-98-4 CAPLUS
 CN Benzamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 287391-99-5 CAPLUS
 CN Benzeneacetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-3,4-dichloro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 287392-00-1 CAPLUS

CN 2-Thiophenebutanamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B




RN 287392-01-2 CAPLUS


CN 9H-Xanthene-9-carboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 287392-02-3 CAPLUS
 CN Benzeneacetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-.alpha.-phenyl- (9CI) (CA INDEX NAME)




RN 287392-03-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 287392-04-5 CAPLUS


CN Benzeneacetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-.alpha.-phenyl- (9CI) (CA INDEX NAME)



RN 287392-05-6 CAPLUS

CN 2H-Isoindole-2-acetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

- C≡C-Me


RN 287392-06-7 CAPLUS

CN Benzamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 287392-07-8 CAPLUS
 CN Benzeneacetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-3,4-dichloro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 287392-08-9 CAPLUS
 CN 3-Quinolinecarboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



PAGE 1-A





PAGE 1-B

\equiv C-Me

RN 287392-09-0 CAPLUS
 CN 9H-Xanthene-9-carboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 287392-10-3 CAPLUS
 CN 1-Isoquinolinecarboxamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-(9CI) (CA INDEX NAME)



RN 287392-11-4 CAPLUS

CN Benzo[b]thiophene-3-acetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-(9CI) (CA INDEX NAME)




—C≡C—Me


RN 287392-12-5 CAPLUS

CN 1H-Indole-3-acetamide, N-[2-[[5-[[4-(2-butynyloxy)phenyl]sulfonyl]-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 287392-13-6 CAPLUS

CN Benzenebutanamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-4-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 287392-14-7 CAPLUS

CN Heptanamide, 2-[[4-(2-butynyloxy)phenyl]sulfonyl]-7-cyano-N-hydroxy- (9CI) (CA INDEX NAME)



RN 287392-17-0 CAPLUS


CN Cyclohexaneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 287392-21-6 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-4-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287392-22-7 CAPLUS


CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-4-methoxy-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287392-24-9 CAPLUS

CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-4-methoxy- (9CI) (CA INDEX NAME)




RN 287392-27-2 CAPLUS


CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-4-chloro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-28-3 CAPLUS
 CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]thio]-3-chloro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-29-4 CAPLUS
 CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-3-chloro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-33-0 CAPLUS
 CN Benzeneacetamide, 4-bromo-.alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-36-3 CAPLUS
 CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-4-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 287392-38-5 CAPLUS
 CN 1-Naphthaleneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-39-6 CAPLUS
 CN 1-Naphthaleneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-40-9 CAPLUS
 CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-4-fluoro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-41-0 CAPLUS
 CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-4-fluoro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 287392-43-2 CAPLUS
 CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-2-methoxy- (9CI) (CA INDEX NAME)




RN 287392-45-4 CAPLUS
 CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-4-ethoxy-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-47-6 CAPLUS
 CN Benzeneacetamide, 3-bromo-.alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287392-48-7 CAPLUS
 CN Benzeneacetamide, 3-bromo-.alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287392-49-8 CAPLUS
 CN Benzeneacetamide, 3-bromo-.alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-51-2 CAPLUS
 CN Butanamide, 2-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287392-52-3 CAPLUS
 CN Butanamide, 2-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287392-53-4 CAPLUS
 CN Butanamide, 2-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-3-methyl- (9CI)
 (CA INDEX NAME)




RN 287392-55-6 CAPLUS
 CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-,
 (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287392-56-7 CAPLUS
 CN Benzeneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-hydroxy-,
 (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287392-58-9 CAPLUS
 CN 2-Naphthaleneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfinyl]-N-
 hydroxy- (9CI) (CA INDEX NAME)




RN 287392-59-0 CAPLUS

CN 2-Naphthaleneacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-61-4 CAPLUS

CN 4-Piperidineacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-62-5 CAPLUS

CN 4-Piperidineacetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-1-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 287392-63-6 CAPLUS

CN 4-Piperidineacetamide, 1-benzoyl-.alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-64-7 CAPLUS

CN 4-Piperidineacetamide, 1-acetyl-.alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 287392-65-8 CAPLUS

CN 2H-Pyran-4-acetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 287392-67-0 CAPLUS

CN 2H-Thiopyran-4-acetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]tetrahydro-N-hydroxy-, 1-oxide (9CI) (CA INDEX NAME)

<-----User Break----->


RN 287392-68-1 CAPLUS

CN 2H-Thiopyran-4-acetamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]tetrahydro-N-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 287393-60-6 CAPLUS

CN 3-Pyridinepropanamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-.alpha.-methyl- (9CI) (CA INDEX NAME)



RN 287393-61-7 CAPLUS

CN Benzenepropanamide, .alpha.-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-.alpha.-methyl-4-[2-(1-piperidinyloxy)ethoxy]- (9CI) (CA INDEX NAME)



IT 287391-65-5D, resin-supported 287391-76-8D, resin-supported 287391-85-9D, resin-supported 287391-95-1D, resin-supported 287392-04-5D, resin-supported 287393-58-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of alkynyl contg. hydroxamic acid compds. as TACE inhibitors)

RN 287391-65-5 CAPLUS

CN 2-Quinolinecarboxamide, N-[5-[[4-(2-butynyloxy)phenyl]sulfinyl]-6-(hydroxyamino)-6-oxohexyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS

IT 367517-41-7P 367517-61-1P 367517-69-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of benzimidazole-, benzoxazole- and benzothiazolesulfonamide amino acid derivs. as selective matrix metalloproteinase inhibitors)

RN 367517-41-7 CAPLUS


CN Benzenepropanamide, .alpha.-[[[2-(heptylthio)-6-benzothiazolyl]sulfonyl]amino]-N-hydroxy-4-(2-propynyloxy)-, (.alpha.R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367517-61-1 CAPLUS

CN Benzenepropanamide, .alpha.-[[[2-(heptylthio)-6-benzothiazolyl]sulfonyl]amino]-N-hydroxy-4-(2-propynyloxy)- (9CI) (CA INDEX NAME)



RN 367517-69-9 CAPLUS

CN Benzenepropanamide, .alpha.-[[[2-(hexylthio)-6-benzothiazolyl]sulfonyl]amino]-N-hydroxy-4-(2-propynyloxy)-, (.alpha.R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

